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The ErbB2 blocker trastuzumab improves survival in oncologic patients, but can cause
cardiotoxicity. The late Na+ current inhibitor ranolazine has been shown to counter
experimental HF, including doxorubicin cardiotoxicity (a condition characterized by
derangements in redox balance), by lowering the levels of reactive oxygen species
(ROS). Since ErbB2 can modulate ROS signaling, we tested whether trastuzumab
cardiotoxicity could be blunted by ranolazine via redox-mediated mechanisms.
Trastuzumab decreased fractional shortening and ejection fraction in mice, but ranolazine
prevented heart dysfunction when co-administered with trastuzumab. Trastuzumab
cardiotoxicity was accompanied by elevations in natriuretic peptides and matrix
metalloproteinase 2 (MMP2) mRNAs, which were not elevated with co-treatment with
ranolazine. Trastuzumab also increased cleavage of caspase-3, indicating activation of
the proapoptotic machinery. Again, ranolazine prevented this activation. Interestingly,
Neonatal Rat Ventricular Myocytes (NRVMs), labeled with MitoTracker Red and treated
with trastuzumab, showed only a small increase in ROS compared to baseline conditions.
We then stressed trastuzumab-treated cells with the beta-agonist isoproterenol to
increase workload, and we observed a significant increase of probe fluorescence,
compared with cells treated with isoproterenol alone, reflecting induction of oxidative
stress. These effects were blunted by ranolazine, supporting a role for INa inhibition in
the regulation of redox balance also in trastuzumab cardiotoxicity.
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INTRODUCTION
ErbB2 (also called HER2) is tyrosine kinase receptor, member of the human epidermal growth
factor receptor family, and is overexpressed in 25–30% of breast cancers (Slamon et al., 1987).
Trastuzumab is the prototypical anti-ErbB2 drug, and the first developed and most widely used
biologic anticancer agent. Since its introduction in 1998, trastuzumab has dramatically improved
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the clinical history of breast cancer patients, but unfortunately it
has been shown to cause cardiac dysfunction (Bloom et al., 2016;
Moslehi, 2016; Zamorano et al., 2016; Armenian et al., 2017),
since ErbB2 has been proven to be an important modulator
of myocardial function (Force et al., 2007; Eschenhagen et al.,
2011). Indeed, in the heart, ErbB2 seems to mediate cell
survival and functionality (De Keulenaer et al., 2010; Ky et al.,
2013; Lim et al., 2015), and also cardiac regeneration (D’Uva
et al., 2015), and it seems to be stimulated upon cardiac
adverse hemodynamics or other stress, such as doxorubicin
(De Keulenaer et al., 2010; Tocchetti et al., 2017). It has been
hypothesized that ErbB2 blockers can hamper cardiomyocytes,
especially when exposed to other stressors, such as pressure or
volume overload or anthracyclines, eventually leading to cardiac
dysfunction (de Korte et al., 2007; Gabrielson et al., 2007; Ewer
and Ewer, 2010). Hence, this co-administration is now possibly
avoided in clinics (Slamon et al., 2001; Suter et al., 2007), since
trastuzumab can exacerbate or induce anthracycline toxicity:
once trastuzumab blocks the protective mechanisms of ErbB2,
the oxidative damage from anthracyclines can increase (Ewer and
Ewer, 2010). Importantly, ErbB2 has been shown to modulate
doxorubicin-induced redox damage (Timolati et al., 2006), while
its blockade is able to induce myocytes death through redox-
dependent pathways (Gordon et al., 2009). In addition, ErbB2
overexpressor mice showed upregulation of antioxidant enzymes
and protection from anthracyclines cardiotoxicity (Belmonte
et al., 2015).
The late Na+ current inhibitor ranolazine has emerged as a
potential therapeutic to treat experimental heart failure (Sabbah
et al., 2002; Rastogi et al., 2008), and has also been recently
indicated as a promising cardio-oncological drug (Minotti, 2013).
We and others (Tocchetti et al., 2014; Cappetta et al., 2017) have
demonstrated that ranolazine is also able to blunt experimental
doxorubicin cardiotoxicity. Also, we had previously shown that
trastuzumab can cause experimental heart dysfunction (Riccio
et al., 2009; Fedele et al., 2012). Hence, here we hypothesize that
ranolazine is also able to blunt heart dysfunction induced by
trastuzumab in animal and cellular models.
MATERIALS AND METHODS
Trastuzumab Treatment Protocol in Vivo
C57Bl/6 mice (2–4 months old, Harlan Italy, San Piero al
Natisone, Udine, Italy) were injected with a cumulative dose
of 2 nM trastuzumab (Genentech, South San Francisco, CA,
USA) via seven daily intraperitoneal injections (2.25 mg/kg i.p.,
TRA group), as for our well-established protocol (Fedele et al.,
2012). No mortality was associated with this dosing regimen.
Another group of mice was treated orally with ranolazine
(Ranexa, Menarini, 305 mg/kg/day, doses comparable Reagan-
Shaw et al., 2008 with those used clinically in humans of 750mg
twice daily, below the human maximal dosing of 1 g twice daily)
for 10 days (RAN group; Tocchetti et al., 2014), and another
group, after 3 days of ranolazine, started receiving trastuzumab
concomitantly with ranolazine for 7 days (RAN+TRA group).
Sham animals were used as controls. For ex vivo analyses,
animals were sacrificed by cervical dislocation after anesthesia
with tilotamine (0.09 mg/g), zolazepam (0.09 mg/g), and 0.01%
atropine (0.0 4 ml/g); hearts were then excised and processed for
further studies. Eight to ten animals per group were studied for all
protocols.
Transthoracic Echocardiography
In vivo cardiac function was assessed by transthoracic
echocardiography in sedated 2- to 4-month-old WT C57BL6
mice (Harlan Italy, San Piero al Natisone, UD, Italy) using a
Vevo 2100 high-resolution imaging system (40-MHz transducer,
VisualSonics, Toronto, ON, Canada). Mice were anesthetized
with Tilotamine (0.09mg/g), Zolazepam (0.09mg/g), and
0.01% atropine (0.04 ml/g). Cardiac function was evaluated by
non-invasive echocardiography in basal conditions, after 7 days
of treatment with trastuzumab, or after 3 days of pre-treatment
with ranolazine followed by co-administration of ranolazine and
trastuzumab for 7 days. Studies and analysis were performed
blinded to heart condition. Data are presented as mean ±
standard error of the mean (SEM) unless otherwise noted.
Between-group differences were assessed by Student’s t-test or
one-way analysis if variance (ANOVA) as appropriate. Statistical
significance was defined as P < 0.05.
The animal experiments described herein were carried out in
accordance with the recommendations of Italian regulations for
experimentation on animals. The protocol was approved by the
ethical committee and met the standards required by Directive
2010/63/EU of the European Parliament.
RNA Extraction and Real-Time PCR
Fresh frozen tissue was mechanically homogenized and total
RNA was extracted by using Trizol (Invitrogen, Milan, Italy)
according to the manufacturer’s protocol. Reverse transcription
of total RNA was performed starting from equal amounts of
total RNA/sample (500 ng) using SuperScript R© III Reverse
Transcriptase (Invitrogen, Milan, Italy). RT-PCR was used to
assess the mRNAs of ANP, MMP2, and GAPDH (the latter
as an internal reference), as previously described (Tocchetti
et al., 2014). Experiments were carried out in triplicate for
each data point, and data analysis was performed with Applied
Biosystems’StepOnePlus
TM
Real-Time PCR System.
Western Blotting Analysis of the Apoptotic
Pathway
Murine hearts were processed as previously described (Tocchetti
et al., 2014). Anti-caspase 3, anti-cleaved caspase 3, anti-
GAPDH (Cell Signaling Technology), or anti-Actin antibody
(Sigma), followed by anti-rabbit, HRP-conjugated IgGs from
goat antiserum (Thermo Scientific) were used to detect
proteins involved in the apoptotic pathway. The signal
from secondary antibodies was visualized by enhanced
chemiluminescence detection (ECL western blotting detection
kit, Thermo Scientific). The signal intensity of reactive bands
was quantitatively measured with a phosphorimager (GS-
710, Biorad) or by the open source software ImageJ (NIH,
USA).
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Isolation and Culture of Neonatal Rat
Ventricular Myocytes (NRVMs)
NRVMs were isolated from 1 to 3 days old Wistar rats. Hearts
were excised, fragmented and dissociated at 4◦C overnight
with an enzyme solution containing trypsin (Invitrogen), under
continuous stirring. The day after, fragments were further
dissociated with an enzymatic solution containing Collagenase
type I (Gibco). Cells were purified and resuspended in growth
medium consisting of MEM (Invitrogen) supplemented with
10% fetal bovine serum (Gibco) and antibiotics (100 U/ml
penicillin and 100µg/ml streptomycin).
Cells were pre-plated for 90min in order to separate NRVMs
from fibroblasts. NRVMs were counted and opportunely diluted
with MEM supplemented with 10% FBS, antibiotics, non-
essential amino acids (NEAA) and 0.1mM BrdU, necessary to
inhibit cell proliferation, and the plated onto slides pre-treated
with gelatin 0.1%.
Measurement of Formation of Reactive
Oxygen Species
NRVMs were seeded in 6-well plates at a density of 3 × 105/well
and ranolazine (10µM) and trastuzumab (2µM), alone or in
combination, were added.
After 24 h, cells were incubated for 15min at 37◦C with
10 nM MitoTracker Red CM-H2XRos (MTR, Molecular Probes,
λec = 579 nm, λem = 599 nm) in HBSS. Following the
incubation, cells were washed twice with HBSS and slides were
analyzed using the fluorescence microscope Zeiss Axlovert 100M
and a 63x oil immersion objective.
In the kinetic experiment, NRVMs were treated with
ranolazine (10µM) and trastuzumab (2µM), alone or in
combination. After 24 h, cells were incubated with 10 nM
MitoTracker Red CM-H2XRos as shown before. Three baseline
images were taken at frame rate 1/5min, and then 4µM
Isoproterenol (ISO) was added for 1 h.
Statistical Analyses
For most studies, between-group differences were assessed
by Student’s t-test or one-way ANOVA as appropriate.
Statistical analysis was performed with OriginPro 8 SR0
v8.0724. Differences among the groups in parameters assessed by
reverse transcription–PCR (RT–PCR) or western blotting were
evaluated using the non-parametric Kruskal–Wallis test and
adjusted for multiple comparisons with the Bonferroni method
Statistical analysis were performed with SPSS statistical package
(14.0 version).
Statistical significance was defined as P < 0.05.
RESULTS
Ranolazine Attenuates
Trastuzumab-Induced Heart Dysfunction in
Mice
First, we tested the beneficial role of ranolazine on trastuzumab
induced cardiotoxicity in vivo in a mouse model. To this
aim, groups of 8–10 mice were treated with trastuzumab
and ranolazine as described in the Methods section.
Echocardiography was performed before and after the
treatments.
After 7 days, in trastuzumab-treated mice, fractional
shortening (FS) decreased to 54 ± 3.86%, p < 0.0005 vs. 60.29
± 2.47% (sham), ejection fraction (EF) to 84.33 ±3.08%, p <
0.0005 vs. 91.26 ± 2.03% (sham). However, in mice treated with
ranolazine plus trastuzumab, FS and EF were not significantly
reduced (FS 59.40± 3.13%; EF 89.80± 2.28%; Figure 1).
Ranolazine Prevents Cardiac Fetal Gene
Reprograming and Extracellular Matrix
Remodeling in Trastuzumab Treated Hearts
At the end of the in vivo treatment, mice were euthanized,
and hearts were removed and processed for mRNA expression
analyses and detection of myocardial stress and apoptosis.
All analyses were performed in parallel experiments on sham
animals. In accordance with the alterations of contractile
function, trastuzumab enhanced ANP and MMP2 mRNAs
compared with sham. However, whenmice were pre-treated with
ranolazine, ANP, and MMP2 mRNA levels were lower compared
to TRA (Figure 2).
Ranolazine Reduces Trastuzumab-Induced
Apoptosis
We then investigated the impact of ranolazine on trastuzumab-
induced cell death. Excised murine hearts of treated mice were
handled as described above, then lysed and analyzed by Western
blotting with an anti-Caspase antibody. Trastuzumab activated
apoptosis significantly, as shown by the enhanced cleavage of
caspase-3. Caspase-3 fragmentation did not occur when mice
were co-administered with RAN+TRA (Figure 3).
Ranolazine Limits the Production of
Reactive Oxygen Species Induced by
Trastuzumab in NRVMs
To test whether ranolazine protective effects are achieved by a
reduction of ROS generated upon trastuzumab administration,
ROS formation was monitored in NRVMs. NRVMs labeled
with MitoTracker Red and treated for 24 h with Trastuzumab
showed a modest increase of probe fluorescence, compared with
untreated cells, reflecting induction of oxidative stress, which was
not blunted by ranolazine.
Considering that trastuzumab exerts its cardiotoxic effects
especially in presence of cardiac stressors (de Korte et al., 2007;
De Keulenaer et al., 2010; Ewer and Ewer, 2010; Tocchetti
et al., 2017), and that the beating heart is normally subject
to preload and afterload, we then incubated NRVM with the
beta stimulator isoproterenol (ISO; Tocchetti et al., 2012) to
simulate workload conditions. Interestingly, the concomitant
administration of TRA and ISO produced a significant increase in
ROS compared to ISO alone, and such increase could be blunted
by RAN (Figure 4).
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FIGURE 1 | Ranolazine protects from trastuzumab-related cardiac dysfunction. Ranolazine blunts reductions in fractional shortening (FS) and ejection fraction (EF)
induced by trastuzumab (**p < 0.01 vs TRA; ***p < 0.001 vs TRA).
FIGURE 2 | Effects of ranolazine on cardiac fetal gene reprogramming. ANP, BNP, and MMP2 mRNA expressions induced by trastuzumab were reduced in mice
pretreated with ranolazine (*p < 0.05 vs. TRA; **p < 0.005; ***p < 0.0005).
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FIGURE 3 | Apoptotic pathway analysis in hearts of treated mice. Caspase 3
activation triggered by trastuzumab, was reduced by ranolazine treatment
(*p < 0.05 vs. TRA; **p < 0.005 vs. TRA; ***p < 0.0005 vs. TRA).
FIGURE 4 | Ranolazine (RAN) reduces Reactive Oxygen Species (ROS)
formation induced by Trastuzumab (TRA) and isoproterenol (ISO). Neonatal
Rat Ventricular Myocytes (NRVMs) untreated or treated for 24 h with 2µM
TRA, with 10µM Ran or with 2µM TRA and 10µM Ran, were incubated for
1 h with 4µM Iso. Microscopy analysis of cells labeled with the fluorescent
probe Mitotracker Red CM-H2XRos was performed to detect the degree of
mitochondrial oxidative stress. Data are normalized to the control after 24 h +
1 h of treatment with isoproterenol. n ISO: 24; n TRA+ISO: 22; n RAN+ISO:
19; n RAN+TRA+ISO: 20. *p < 0.05 vs. TRA; **p < 0.01 vs. TRA.
DISCUSSION
The introduction of trastuzumab in therapeutic protocols for
ErbB2+ breast cancer has revolutionized the prognosis of
patients affected by this disease, but unfortunately this therapy
is characterized with a relevant incidence of cardiac dysfunction
and HF, especially when associated with anthracyclines. We
(Tocchetti et al., 2014) and others (Cappetta et al., 2017) have
shown that the late INa inhibitor ranolazine is able to blunt
cardiac dysfunction induced by anthracyclines by decreasing
ROS production. The data presented here suggest that ranolazine
is also able to blunt trastuzumab cardiotoxicity, and this effect
seems to involve a reduction in oxidative stress. Indeed, redox
mechanisms have also been proposed for the neuregulin/ErbB2
pathway. This pathway has been shown to play a role in
modulating the increase in ROS caused by doxorubicin in animal
models (Timolati et al., 2006), suggesting that cardiotoxicity
from ErbB2 blockade can also involve a dysregulation of
redox homeostasis (Mercurio et al., 2016). Importantly, beside
anthracyclines (Menna et al., 2012; Sawyer, 2013; Steˇrba et al.,
2013; Ghigo et al., 2016), redox abnormalities are involved in
the pathophysiology of cardiotoxic effects caused by several
antineoplastic drugs (Ferroni et al., 2011), including new biologic
anti-cancer drugs, such as intracellular signaling inhibitors, that
are increasingly used in recent years (Tocchetti et al., 2017).
Such drugs may be cardiotoxic, since they block pathways that
are major modulators of myocardial function, especially under
conditions of cardiac stress, such as hypertension or hypertrophy
(Suter and Ewer, 2013), with mechanisms of action that often
involve redox dysregulation as well.
The importance of ErbB2 in the heart has been particularly
emphasized by seminal studies that demonstrated that ErbB2
cardiac KO mice were affected by dilated cardiomyopathy,
with increased susceptibility to anthracycline-induced damage
to cardiomyocytes (Crone et al., 2002; Ozcelik et al., 2002).
Conversely, cardiac ErbB2 overexpressor mice showed lower
levels of ROS in mitochondria, with reduced ROS levels
and less cell death in neonatal cardiomyocytes isolated from
ErbB2(tg) hearts upon administration of anthracyclines, due
to increased levels of glutathione peroxidase 1 (GPx1) protein
and GPx activity, with enhanced levels of two known GPx
activators, c-Abl, and Arg (Belmonte et al., 2015; Tocchetti et al.,
2017). Furthermore, block of ErbB2 has been correlated with
cardiomyocyte death through reactive oxygen species-dependent
pathways (Gordon et al., 2009).
Along this line, our results in NRVM show that attenuation
of trastuzumab toxicity with ranolazine is indeed obtained
by reducing ROS production, and our in vivo data show
better LV function with ranolazine+trastuzumab compared with
trastuzumab alone. The fact that trastuzumab elicited only a
modest rise in ROS in non-stressed NRVM is compatible with
the cardiotoxic effect of ErbB2 blockers that might be negligible
per se, but exacerbated when administered under conditions of
cardiac stress or in previously diseased hearts (e.g., increased
pressure or volume overload) or in presence of cardiovascular
risk factors (age, obesity, smoking, hypertension, previous
exposure to anthracyclines; Denegri et al., 2016; Tocchetti et al.,
2017).
The inhibition of late INa with ranolazine has been proposed
as a therapeutic strategy in many in vivo and in vitro models
of heart dysfunction (Sabbah et al., 2002; Rastogi et al., 2008;
Coppini et al., 2013, 2017) and in particular, ranolazine has
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been shown to be able to blunt LV dysfunction in experimental
models of doxorubicin cardiotoxcicity by lowering oxidative
stress (Tocchetti et al., 2014; Cappetta et al., 2017). By reducing
elevated [Na+]i levels that, are commonly elevated in conditions
of cardiac dysfunction (Bers, 2001; Pieske and Houser, 2003),
ranolazine could prevent calcium overload and the occurrence
of oxidative damage by reducing ROS production, with an
advantage over ordinary antioxidant treatments that counteract
ROS after their generation (Zeitz et al., 2002; Maack et al., 2006;
Song et al., 2006; Wagner et al., 2006; Erickson et al., 2008;
Kohlhaas et al., 2010; Tocchetti et al., 2014).
In the setting of heart disease, ROS play a role in
pathophysiological remodeling, cellular death, and LV
dysfunction (Sawyer et al., 2002; Giordano, 2005; Takimoto
and Kass, 2007; Nediani et al., 2011). The molecular signaling
pathways that link ROS to LV hypertrophy, remodeling, and
failure include alpha- and beta-adrenergic and angiotensin
II (AT1) receptor stimulation, as well as modifications of a
wide number of proteins that include stress kinases, nuclear
transcription factors, collagen and metalloproteinases, calcium
channels, myofilaments and proteins involved in the excitation–
contraction coupling machinery. A key role is played by a rise in
cytosolic Ca2+ levels that lead to expression changes of several
genes involved in cardiac pathophysiological hypertrophy and
remodeling of the heart (Arcaro et al., 2016) with increases in
interstitial fibrosis and expression of profibrotic genes (Zhao
et al., 2010). Abnormalities of the extracellular matrix and
adverse remodeling are also exacerbated by ROS (Kandasamy
et al., 2010). Importantly, our data show that ranolazine
is able to blunt the effects produced by trastuzumab on
important components of LV remodeling such as myocyte
death and fibrosis, and to reverse the expression changes
of important genes such as NPs and MMPs, eventually
mitigating the occurrence of cardiac dysfunction measured by
echocardiography.
LIMITATIONS OF THE STUDY
In human pathology trastuzumab is administered to cancer
patients, while here we studied experimental trastuzumab
cardiotoxicity in C57BL6 mice without cancer. Of course,
further studies in mice with cancer will have to be performed.
Nevertheless, C57BL6 mice, that are commonly used in models
of experimental heart failure, also have a compromised immune
system that in part may mimic cancer.
CONCLUSIONS
Our data support previous findings on the efficacy of ranolazine
in experimental heart dysfunction (Sabbah et al., 2002; Rastogi
et al., 2008; Coppini et al., 2013, 2017; Tocchetti et al., 2014;
Cappetta et al., 2017). We acknowledge that further experiments
may be necessary to conclude that the mechanism of action
involves the levels of ROS, also considering that ranolazine
has been recently shown to be able to antagonize β-adrenergic
stimulation and decrease myofilaments Ca2+ sensitivity (Flenner
et al., 2016), with little therapeutic efficacy in a HCM murine
model in vivo. Nevertheless, we show that in the cardio-
oncologic setting, beside doxorubicin cardiotoxicity (Tocchetti
et al., 2014; Cappetta et al., 2017), RAN could also be a
promising cardioprotective drug in the setting of trastuzumab
toxicity. More efforts involving both experimental and clinical
studies will be needed in order to establish whether ranolazine
might be introduced clinically in the therapeutic strategies that
aim at addressing cardiotoxicity induced by trastuzumab or
anthracyclines.
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